Illumina Launches New Software Support Program for Downstream Analysis of Microarray Data.Illumina*Connect Significantly Expands Reach and Breadth of Genomics Solutions Through Key Third-Party Software Partnerships SAN DIEGO San Diego (săn dēā`gō), city (1990 pop. 1,110,549), seat of San Diego co., S Calif., on San Diego Bay; inc. 1850. San Diego includes the unincorporated communities of La Jolla and Spring Valley. Coronado is across the bay. , Calif. -- Illumina, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :ILMN) today announced the launch of Illumina*Connect, a bioinformatics software partnership program established to advance data integration and analysis. This program offers Illumina customers seamless access to third-party bioinformatics providers of advanced data analysis applications for processing Illumina array data. Customers who have upgraded to Illumina's new BeadStudio 3.0 Data Analysis Software for analyzing genotyping, gene expression, and copy number variation (CNV CNV Choroidal Neovascularization (eye disorder) CNV Christelijk Nationaal Vakverbond CNV Copy Number Variation CNV Conveyor CNV Chief of Navy CNV Continuous Normal Voltage CNV Crypto Net Variable CNV Could Not Verify ) analysis can now take full advantage of additional statistical and advanced algorithms afforded by this new program. Illumina*Connect (www.illumina.com/IlluminaConnect) supports partnerships with several leading bioinformatics software vendors of genotyping and gene expression data analysis software. As part of this program, vendors will create customized plug-ins to Illumina's BeadStudio 3.0 Data Analysis Software that facilitates data exchange between Illumina data and the third-party software applications. Participating vendors currently include Biocomputing Biocomputing can mean at least two different things:
"We're excited to be an Illumina Connect partner and enhance the already strong capabilities of JMP JMP Jump JMP Java Memory Profiler JMP Joint Manpower Program JMP Joint Management Plan JMP Joint Marketing Program JMP JCL Manipulation Program JMP Joint Mission Planning (US DoD) JMP Joint Military Program Genomics software for processing high-quality array data from Illumina," said Russ Wolfinger, Ph.D., SAS Director of Scientific Discovery and Genomics. "Researchers will find that statistical discovery from hundreds of thousands of genetic marker genetic marker n. A gene phenotypically associated with a particular, easily identified trait and used to identify an individual or cell carrying that gene. , copy number, and expression measurements has never been easier." Illumina*Connect is already providing significant benefit to the scientific community. In a recent collaboration with Illumina, Golden Helix developed a BeadStudio plug-in that enables researchers to export genotype data in an exceedingly compact storage format. This format enables efficient sharing and analysis by users of Golden Helix' popular genetic analysis program, HelixTree, and also streamlines the transfer, management, and downstream analysis of large-scale genetic data. "Golden Helix provides the genetic research community with powerful software tools that help researchers overcome the statistical and technical challenges of whole genome analysis," said Christophe Lambert, Ph.D., President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Golden Helix. "Illumina*Connect offers an exciting opportunity for Golden Helix and Illumina to work together to help the scientific community to streamline their data analysis processes." "We recognize the critical role that software and hardware support plays in genomic research, where scientists are seeking more powerful data analysis and data management tools for handling large genomic-scale analysis studies," said Omoshile Clement, Ph.D., Senior Product Manager, Platforms at Illumina. "With Illumina*Connect we have established a highly connected network that ensures solutions for our customers conducting biological research in a wide range of areas such as genome-wide association studies, differential expression analysis, and chromosomal copy number analysis studies." About Illumina*Connect Illumina has initiated partnerships with leading bioinformatics software vendors in DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. and RNA RNA: see nucleic acid. RNA in full ribonucleic acid One of the two main types of nucleic acid (the other being DNA), which functions in cellular protein synthesis in all living cells and replaces DNA as the carrier of genetic microarray technologies. For more information about Illumina*Connect, please visit www.illumina.com/illuminaConnect.com. About Illumina Illumina (www.illumina.com) is developing next-generation tools for the analysis of genetic variation and function. "Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. " Statement under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995: This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are the costs and outcome of Illumina's litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. with Affymetrix, our ability to effectively integrate our recent acquisition of Solexa, Inc., Illumina's ability to further develop and commercialize its BeadArray technologies and to deploy new gene expression and genotyping products and applications for its platform technology, Illumina's ability to manufacture robust Sentrix(R) arrays and Oligator(R) oligonucleotides, Illumina's ability to scale and integrate CyVera technology, and other factors detailed in the Company's filings with the Securities and Exchange Commission including its recent filings on Forms 10-K and 10-Q or in information disclosed in public conference calls, the date and time of which are released beforehand. Illumina disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion